Hospitals are the largest end‑user segment — they diagnose and treat tularemia cases. But research institutions are the fastest‑growing. The tularemia market research study shows that research labs are growing at over 5% CAGR, driven by government funding for biodefense. Why? Because tularemia is a potential bioweapon, and we need better vaccines and rapid diagnostics.

What's happening in research? Vaccine candidates (live attenuated, subunit) are in animal trials. The tularemia market trends highlight that the fastest‑growing infection type is pneumonic tularemia, because it's the most likely form in a bioterrorism scenario (aerosol release).

But research is slow. Tularemia is a rare disease, so clinical trials are hard to recruit for. And there's no commercial market for a vaccine — that's why government funding is essential.

The bottom line: tularemia research is a public good, not a profit centre. If you're a scientist, consider working on neglected pathogens. If you're a citizen, support funding for biodefense.